Bristol-Myers Squibb Company
Profile managed by Bizz IdDescription
Products
16 productsBrand: Orencia.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
In combination with nivolumab. 1L extensive-stage small cell lung cancer. Phase 3.
Under development
Finished product (FDF)
Verified on 2026-10-21
Brand: Nulojix.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
CD19 T-cell engager. Autoimmune diseases. Phase 1.
Under development
Finished product (FDF)
Verified on 2026-10-21
CD33-GSPT1 antibody-drug conjugate. Acute myeloid leukemia. Phase 1.
Under development
Finished product (FDF)
Verified on 2026-10-21
Brand: Empliciti.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
With Ono. With pumitamig in 1L NSCLC in Phase 2; solid tumors in Phase 1.
Under development
Finished product (FDF)
Verified on 2026-10-21
Brand: Yervoy.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
With SystImmune. EGFR-mutated NSCLC in Phase 3; TNBC and urothelial cancer in Phase 2; solid tumors in Phase 1.
Under development
Finished product (FDF)
Verified on 2026-10-21
Brand: Reblozyl (legacy Celgene product). 1L transfusion-dependent myelofibrosis-associated anemia in registration (US), with Merck.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Alzheimer's disease. Phase 2.
Under development
Finished product (FDF)
Verified on 2026-10-21
Brand: Opdivo. Adjuvant hepatocellular carcinoma in Phase 3 (with Ono).
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Opdivo Qvantig. Nivolumab and hyaluronidase. With Yervoy in 1L non-small cell lung cancer in Phase 2.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Opdualag. High-dose (HD) formulation in 1L non-small cell lung cancer (PD-L1 ≥1%) in Phase 3.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
With Zenas BioPharma. IgG4-related disease. Phase 3.
Under development
Finished product (FDF)
Verified on 2026-10-21
BNT327/BMS-986545, with BioNTech. ES-SCLC, NSCLC, TNBC and MSS colorectal cancer in Phase 3; 2L NSCLC and gastric cancer in Phase 2; HCC and RCC in Phase 1.
Under development
Finished product (FDF)
Verified on 2026-10-21